IL-2 Effective in Metastatic Renal Cell Carcinoma (RCC) Patients with Favorable Histologies
the Cancer Therapy Advisor take:
Although the range of therapies for metastatic renal cell carcinoma (mRCC) is growing, managing the disease is still a challenge for clinicians.
The standard of care for mRCC is vascular endothelial growth factor (VEGF)-targeted therapy; although this treatment is effective and well-tolerated, the responses seen in patients are often not long-lasting. High-dose interleukin-2 (IL-2), a protein that can activate the immune system, can produce durable complete responses, but can elicit significant toxicities and therefore its use is limited.
At the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland, researchers from the Christie Hospital in Manchester, United Kingdom presented a retrospective analysis of 180 patients with mRCC who received high dose IL-2 at their institution over the last 10 years. One hundred forty-five of these patients were treatment-naïve, and 35 had been previously treated.
Overall, the outcomes for these patients were similar for both groups; of those patients who achieved a complete response, 75% are alive and disease-free (median overall survival not yet reached), and there was no difference in response or survival rate between the two groups.
The results of this study show that high-dose IL-2 can be safe and effective in mRCC patients who have been classified as having a “favorable” histology, and the researchers indicated that it should be considered as first- or second-line therapy in these patients.
Although the range of therapies for mRCC is growing, managing the disease is still a challenge for clinicians.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia